Product Information
DYMISTA NASAL SPRAY is a brand product labeled by Viatris Specialty LLC, priced at $9.1399 per GM under NDC 00037024523. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on May 1, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Azelastine Hydrochloride and Fluticasone Propionate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
137; 50 ug/1; ug/1
Manufacturer
Viatris Specialty LLCNDC
00037024523
Classification
Brand
Dosage Form
SPRAY, METERED
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATEApproval Type
New Drug (NDA)
FDA Application
NDA202236FDA Approved
5/1/2012
TE Code
AB
On Market Since
10/1/2016
Pharmacological Classes
Price Statistics
The NADAC for DYMISTA NASAL SPRAY has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 56.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.1399 per GM |
|---|---|
| All-time high | $9.1784 (Oct 15, 2025) |
| All-time low | $5.8239 (Mar 19, 2014) |
| 52-week high | $9.1784 |
| 52-week low | $9.1399 |
| Median price | $8.3313 |
| Average price | $7.9526 |
| Largest weekly change | +10.0% (Jan 21, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 78% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Viatris Specialty LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Azelastine Hydrochloride and Fluticasone Propionate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Corticosteroid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DYMISTA NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for DYMISTA NASAL SPRAY, manufactured by Viatris Specialty LLC, is $9.1399 per GM (NDC 00037024523), effective Sep 30, 2026.
How has the price of DYMISTA NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for DYMISTA NASAL SPRAY has risen 56.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DYMISTA NASAL SPRAY?
Since Nov 28, 2013, the NADAC for DYMISTA NASAL SPRAY has ranged from a low of $5.8239 (Mar 19, 2014) to a high of $9.1784 (Oct 15, 2025), with a median of $8.3313 per GM.
Are there cheaper alternatives to DYMISTA NASAL SPRAY?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, AZELASTIN-FLUTIC 137-50 MCG SPR, is $2.0210 per GM — about 78% below DYMISTA NASAL SPRAY.
Who manufactures DYMISTA NASAL SPRAY?
DYMISTA NASAL SPRAY (NDC 00037024523) is labeled by Viatris Specialty LLC, and CMS classifies it as a brand product.